Umeå University's logo

umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Differential modulation of SARS-CoV-2 infection by complement factor H and properdin
Department of Veterinary Medicine, CAVM), United Arab Emirates University, Al Ain, United Arab Emirates; Zayed Centre for Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
Umeå University, Faculty of Medicine, Department of Clinical Microbiology.
Biomedical Informatics Centre, ICMR-National Institute for Research in Reproductive and Child Health, Maharashtra, Mumbai, India.
Biomedical Informatics Centre, ICMR-National Institute for Research in Reproductive and Child Health, Maharashtra, Mumbai, India.
Show others and affiliations
2025 (English)In: Frontiers in Immunology, E-ISSN 1664-3224, Vol. 16, article id 1620229Article in journal (Refereed) Published
Abstract [en]

Introduction: An unbalanced immune response and excessive inflammation are the major hallmarks of severe SARS-CoV-2 infection, which can result in multiorgan failure and death. The dysregulation of the complement system has been shown in various studies as a crucial factor in the immunopathology of SARS-CoV-2 infection. Complement alternative pathway has been linked to the excessive inflammation in severe SARS-CoV-2 infection in which decreased levels of factor H (FH) and elevated levels of properdin (FP) were observed. The current study investigated the potential immune protective roles of FP and FH against SARS-CoV-2 infection.

Methods: The interactions between FH and FP and the SARS-CoV-2 spike (S) and its receptor binding domain (RBD) were evaluated using direct ELISA. The cell binding and luciferase-based viral entry assays utilising S protein expressing lentiviral pseudotypes were used to evaluate the possible modulatory effects of FH, FP, and recombinant thrombospondin repeats 4 and 5 (TSR4 + 5) on SARS-CoV-2 cell entry. Using RT-qPCR, we also assessed the immunomodulatory roles of FH and FP in the cytokine response induced by SARS-CoV-2 pseudotypes.

Results: FH and FP were found to bind to both the RBD and SARS-CoV-2 S proteins. The treatment of FP or TSR4 + 5 enhanced cell binding and entry of SARS-CoV-2 pseudotypes that was administered in A549 cells expressing human ACE2 and TMPRSS2 (A549-hACE2+TMPRSS2 cells). FP increases the affinity between host ACE2 and SARS-CoV-2, according to in silico work. In A549-hACE2+TMPRSS2 cells, the effect of FP on viral cell entry and binding was counteracted by anti-FP antibody treatment. On the other hand, SARS-CoV-2 lentiviral pseudotypes’ cell entry and binding were decreased by FH treatment. The A549-hACE2+TMPRSS2 cells that were challenged with SARS-CoV-2 alphaviral pseudotypes (expressing spike, envelope, nucleocapsid, and membrane proteins) pre-treated with FP or TSR4+5 showed an upregulation of pro-inflammatory cytokine transcripts, including NF-κB and IL-1β, IL-8, IL-6, TNF-α, IFN-α, and RANTES. Contrary to this, the expression of these pro-inflammatory cytokines was downregulated by FH treatment. FH treatment decreased S protein-mediated NF-κB activation, but FP treatment enhanced it in A549-hACE2+TMPRSS2 cells.

Discussion: These results imply that FH may function as a SARS-CoV-2 cell entry and binding inhibitor, reducing the inflammatory response linked to infection independently of complement activation. FP could aid cell viral entry and binding and aggravate hyperinflammation that might contribute to the severity of the infection.

Place, publisher, year, edition, pages
Frontiers Media S.A., 2025. Vol. 16, article id 1620229
Keywords [en]
alternative pathway, complement system, COVID-19, cytokine response, factor H, innate immune system, properdin, SARS-CoV-2
National Category
Immunology in the Medical Area
Identifiers
URN: urn:nbn:se:umu:diva-243975DOI: 10.3389/fimmu.2025.1620229ISI: 001560056100001PubMedID: 40895576Scopus ID: 2-s2.0-105014518898OAI: oai:DiVA.org:umu-243975DiVA, id: diva2:1995798
Funder
Wellcome trustAvailable from: 2025-09-08 Created: 2025-09-08 Last updated: 2025-09-08Bibliographically approved

Open Access in DiVA

fulltext(4975 kB)16 downloads
File information
File name FULLTEXT01.pdfFile size 4975 kBChecksum SHA-512
3d35014016b236bffc96b7b00464d678370a5902e8b5580f7fea7742224f7a84099db4e52e1335439221bb2a8fa02499264298de9a11bc8359f390ab5b25e57c
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Varghese, Praveen M.Beirag, Nazar

Search in DiVA

By author/editor
Varghese, Praveen M.Beirag, Nazar
By organisation
Department of Clinical Microbiology
In the same journal
Frontiers in Immunology
Immunology in the Medical Area

Search outside of DiVA

GoogleGoogle Scholar
Total: 18 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 757 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf